Loading clinical trials...
Loading clinical trials...
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A in Adult HIV-infected Subjects
Conditions
Interventions
Herpes Zoster Vaccine GSK1437173A
Placebo
Locations
15
United States
GSK Investigational Site
Long Beach, California, United States
GSK Investigational Site
San Francisco, California, United States
GSK Investigational Site
Orlando, Florida, United States
GSK Investigational Site
Santa Fe, New Mexico, United States
GSK Investigational Site
Dallas, Texas, United States
GSK Investigational Site
Hanover, Lower Saxony, Germany
Start Date
September 30, 2010
Primary Completion Date
July 6, 2012
Completion Date
May 14, 2013
Last Updated
April 30, 2018
NCT07378059
NCT06932523
NCT06903078
NCT06449547
NCT07481604
NCT07354659
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions